Although several studies have shown that mTORC1 often represses mTORC2 activity38, developing dual-inhibitors for both mTORC1 and mTORC2 has been a major approach of targeting the mTOR pathways for cancer treatment, and these inhibitors have exhibited limited clinical benefits39. Here, MTOR is linked to cancer.